Hudson Bay Capital Management
ALT icon

Hudson Bay Capital Management’s Altimmune ALT Stock Holding History

Hudson Bay Capital Management’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-50,000
Closed -$333K – 844
2024
Q2 		$333K Buy
+50,000
New +$369K ﹤0.01% 655

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Hudson Bay Capital Management's ALT Position: Q1 2023 in Review

Hudson Bay Capital Management sold out of Altimmune (ALT) in Q1 2023, closing a stake of 20,731 shares — an estimated $341K sold.

Hudson Bay Capital Management first reported a position in ALT in Q3 2014 and held it in 16 quarters. The position peaked at $8.35M in Q2 2020. 132 funds tracked by Wall St. Rank hold ALT as of Q1 2023.

  • Hudson Bay Capital Management reported no remaining Altimmune position as of Q1 2023 after selling out during the quarter.
  • Hudson Bay Capital Management sold 20,731 Altimmune shares in Q1 2023, an estimated $341K.
  • Hudson Bay Capital Management first reported a position in Altimmune in Q3 2014 and held it in 16 quarters.
  • Hudson Bay Capital Management's Altimmune position peaked at $8.35M in Q2 2020.
  • 132 funds tracked by Wall St. Rank held Altimmune as of Q1 2023.

Based on Hudson Bay Capital Management's 13F filing for Q1 2023, filed 15 May 2023.